Manufacturing
-
Novo to expand French plant in GLP-1 production push
The planned $2.3 billion investment follows an earlier $6 billion commitment to expand manufacturing for drugs like its in-demand medicine Wegovy.
By Delilah Alvarado • Nov. 27, 2023 -
Sponsored by Cognizant
Data infrastructure excellence changing the shape of biopharma manufacturing
Biopharma companies capture data across a variety of different fronts and, so this data must be managed effectively in order to unlock business efficiencies and drive improvements.
Nov. 20, 2023 -
Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up
Following the approval of Zepbound, Lilly is adding capacity to avert shortages and restricted access.
By Jonathan Gardner • Nov. 17, 2023 -
Sponsored by Emergent
3 things manufacturers need to know about the new Annex 1 revision
As biopharmaceutical organizations around the globe adjust to the new guidelines, Baroni shared insights on three things they need to know about Annex 1.
Nov. 13, 2023 -
Obesity drugs
Novo takes aim at obesity drug shortages with $6B manufacturing plan
The maker of Wegovy and Ozempic plans to expand production in its home country of Denmark to help meet surging demand for the GLP-1 drugs.
By Ned Pagliarulo • Nov. 10, 2023 -
Sponsored by PHC Corporation of North America
Futureproofing your lab to meet tomorrow’s sustainability standards
Industry-leading cold storage manufacturers are engineering new solutions that can reliably meet performance benchmarks while consuming far less energy than yesterday’s ULT and laboratory-grade freezers.
Nov. 6, 2023 -
Sponsored by NTT DATA
[Podcast] Secure Innovation: How Life Sciences and Pharmaceutical Companies Can Safely Seize Opportunity
This podcast series explores how life sciences companies can bolster their cybersecurity while growing their business.
Updated Nov. 28, 2023 -
With $56M, a Mayo Clinic-backed startup takes aim at radiopharmaceutical roadblocks
Nucleus RadioPharma, a contract developer and manufacturer, is expanding at a time when investment is pouring into the radiopharmaceutical drug field.
By Gwendolyn Wu • Oct. 17, 2023 -
Bayer opens California plant to make cell therapies
The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock.
By Delilah Alvarado • Oct. 10, 2023 -
Sponsored by MMIT
Using real-world data to improve patient access to oncology therapies
Oncology manufacturers can improve access by using claims, labs, pathway and policy data to address misalignment.
By Carolyn Zele, Solution Consulting Advisor, MMIT • Oct. 9, 2023 -
Lilly eczema drug turned back by FDA over manufacturing
The rejection of lebrikizumab is Lilly’s second for an immunology drug this year, following a complete response letter for mirikizumab in April.
By Delilah Alvarado • Oct. 2, 2023 -
Sponsored by BioPharmaSpec
Process-related impurities: Looking beyond the API for safer biotherapeutics
De-risk your biomanufacturing- an essential mini-guide to detection and quantitation of residuals.
Oct. 2, 2023 -
Novo Nordisk parent backs cell therapy manufacturing facility
The Novo Nordisk Foundation’s planned manufacturing facility will help both private companies and academic researchers develop new cell therapies.
By Jonathan Gardner • Sept. 21, 2023 -
Sponsored by OM1
Reclaiming registries for integrated evidence generation throughout the product life cycle
As integrated evidence generation takes center stage for driving evidence-based decision making across the product life cycle, automated registries just might be the linchpin that pulls it all together.
By Richard Gliklich, MD, CEO, OM1 • Sept. 18, 2023 -
Manufacturing delays under-the-skin Tecentriq shot in US
Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.
By Jonathan Gardner • Sept. 8, 2023 -
Catalent expands board in deal with activist investor Elliott
The CDMO is adding four new independent directors to its board, and has set up a committee to review its business and capital allocation priorities.
By Ned Pagliarulo • Aug. 29, 2023 -
Startup Cellares adds $255M as investors pour cash into cell therapy production
Bristol Myers Squibb is among those backing the company, which claims the manufacturing capacity at its New Jersey plant can surpass that of conventional CDMO facilities.
By Kristin Jensen • Aug. 24, 2023 -
Sponsored by MilliporeSigma
5 ways experience matters in gene therapy manufacturing
By partnering with an accomplished CTDMO, gene therapy innovators can benefit from guidance and support.
Aug. 21, 2023 -
Emergent to lay off around 400 in pivot away from contract manufacturing
The job cuts will affect “all areas of the company” and, combined with other cost-reduction efforts, lead to annualized savings of over $100 million, Emergent said.
By Jacob Bell • Aug. 8, 2023 -
Sponsored by Center for Breakthrough Medicines
Cell and gene therapy is coming of age
Outsourcing in the cell and gene therapy industry is booming and no longer considered just a “trend.”
July 24, 2023 -
Sponsored by Altasciences
Optimize your drug development timeline with liquid-filled, hard-shell capsules
With this highly marketable dosage form, scientists can effectively formulate poorly soluble drugs and supplements, while reducing development time and costs.
July 17, 2023 -
Sponsored by Center for Breakthrough Medicines
Overcoming AAV manufacturing challenges
Overcome issues with AAV vector scalability and reproducibility. Enable a wider application of gene therapies in a cost-effective and sustainable way.
July 10, 2023 -
Sponsored by Emergent
4 steps for a smooth tech transfer when working with a CDMO
When developing a new drug product, quality, safety and timing are critical. A CDMO can be a valuable partner to help mitigate risks.
June 20, 2023 -
Ferring, with manufacturing update, takes a step towards first gene therapy sales
The FDA has cleared Ferring’s planned scale-up process for its bladder cancer treatment Adstiladrin, which the company plans to make available in the U.S. later this year.
By Delilah Alvarado • June 13, 2023 -
Novo Nordisk to invest over $2B in drug ingredient production
The company said the spending will help it manufacture future treatments for chronic diseases, adding to a string of recent plant investments.
By Delilah Alvarado • June 12, 2023